2018
IC‐P‐220: CLINICAL UPDATE: 18F‐PI‐2620, A NEXT GENERATION TAU PET AGENT EVALUATED IN SUBJECTS WITH ALZHEIMER'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY
Stephens A, Seibyl J, Mueller A, Barret O, Berndt M, Madonia J, Kroth H, Bullich S, Pfeifer A, Muhs A, Tamagnan G, Marek K, Dinkelborg L. IC‐P‐220: CLINICAL UPDATE: 18F‐PI‐2620, A NEXT GENERATION TAU PET AGENT EVALUATED IN SUBJECTS WITH ALZHEIMER'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY. Alzheimer's & Dementia 2018, 14: p179-p179. DOI: 10.1016/j.jalz.2018.06.2287.Peer-Reviewed Original Research
2017
[IC‐01–05]: FIRST‐IN‐HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18‐F PI‐2620 IN ALZHEIMER's DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLS
Barret O, Seibyl J, Stephens A, Madonia J, Alagille D, Mueller A, Berndt M, Kroth H, Capotosti F, Muhs A, Pfeifer A, Tamagnan G, Dinkelborg L, Marek K. [IC‐01–05]: FIRST‐IN‐HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18‐F PI‐2620 IN ALZHEIMER's DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLS. Alzheimer's & Dementia 2017, 13: p3-p4. DOI: 10.1016/j.jalz.2017.06.2625.Peer-Reviewed Original Research
2015
Synthesis of 3‐[18F]Fluoro‐5‐(2‐Pyridinylethynyl)Benzonitrile ([18F]FPEB)
Liang S, Yokell D, Jackson R, Rice P, Livni E, Alagille D, Tamagnan G, Collier T, Vasdev N. Synthesis of 3‐[18F]Fluoro‐5‐(2‐Pyridinylethynyl)Benzonitrile ([18F]FPEB). 2015, 41-51. DOI: 10.1002/9781118834114.ch5.Peer-Reviewed Original ResearchMetabotropic glutamate receptor subtype 5Regional brain concentrationsHealthy human subjectsBrain concentrationsBrain penetranceMGluR5 antagonistSubtype 5Parkinson's diseasePathologic processesAlzheimer's diseaseNeuropsychiatric disordersNeurodegenerative diseasesDiseaseHigh potencyHuman subjectsEvidence pointsFragile X syndromeControl testsRadiochemical purityCritical roleX syndromeMGluR5SyndromeAntagonistAbnormalities
2008
P4‐346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease
Siemers E, Friedrich S, Dean R, Sethuraman G, DeMattos R, Jennings D, Tamagnan G, Marek K, Seibyl J. P4‐346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease. Alzheimer's & Dementia 2008, 4: t774-t774. DOI: 10.1016/j.jalz.2008.05.2416.Peer-Reviewed Original Research